Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus 1

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Immunology

• Publication date

  2003-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.171.9.4898PMID 14568971
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.

  2003cited by this paper
• Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide 1

  2003cited by this paper
• Tumor‐specific shared antigenic peptides recognized by human T cells

  2002cited by this paper
• Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

  2002cited by this paper
• Dose-related effects of smallpox vaccine.

  2002cited by this paper
• Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells

  2002cited by this paper
• A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes.

  2001cited by this paper
• A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3

  2001cited by this paper
• Principles and Practice of the Biologic Therapy of Cancer

  2000cited by this paper
• A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules.

  2000cited by this paper
• Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.

  1999cited by this paper
• Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

  1999cited by this paper
• Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes

  1999cited by this paper
• Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1

  1999cited by this paper
• Estimation of the frequencies of anti‐MAGE‐3 cytolytic T‐lymphocyte precursors in blood from individuals without cancer

  1998cited by this paper
• Phenotypic Analysis of Antigen-Specific T Lymphocytes

  1996cited by this paper
• Expression of MAGE genes in primary and metastatic cutaneous melanoma

  1995cited by this paper
• Safe and effective poxvirus vectors--NYVAC and ALVAC.

  1994cited by this paper
• HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs.

  1993cited by this paper
• An experimentally validated panel of subfamily‐specific oligonucleotide primers (Vα1‐w29/Vβ1‐w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction

  1992cited by this paper
• Spontaneous regression of subcutaneous metastasis of cutaneous melanoma.

  1992cited by this paper
• Immunisation with canarypox virus expressing rabies glycoprotein.

  1992cited by this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  1991cited by this paper

• Tuning the sensitivity of mechanosensory receptors through histidine scanning.

  2026cites this paper
• Comprehensive self-antigen screening to assess cross-reactivity in promiscuous T-cell receptors

  2026cites this paper
• Comprehensive Functional Self-Antigen Screening to Assess Cross-Reactivity in a Promiscuous Engineered T-cell Receptor

  2025cites this paper
• Serum starvation-induced cholesterol reduction increases melanoma cell susceptibility to cytotoxic T lymphocyte killing

  2025cites this paper
• A synthetic cytotoxic T cell platform for rapidly prototyping TCR function

  2023cites this paper
• High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity.

  2022cites this paper
• CRISPR-targeted display of functional T cell receptors enables engineering of enhanced specificity and prediction of cross-reactivity

  2020cites this paper
• Current status of virus-vectored vaccines against pathogens that affect poultry.

  2020cites this paper
• Novel technologies for interrogating T cell recognition

  2019cites this paper
• T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation

  2019cites this paper
• Identification of novel human leukocyte antigen‐A*11:01‐restricted cytotoxic T‐lymphocyte epitopes derived from osteosarcoma antigen papillomavirus binding factor

  2019cites this paper
• T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes.

  2019cites this paper
• The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer

  2018cites this paper
• Development of a T‐cell receptor multimer with high avidity for detecting a naturally presented tumor‐associated antigen on osteosarcoma cells

  2018cites this paper
• MAGE-A Antigens and Cancer Immunotherapy

  2017cites this paper
• L-Rhamnose Enhances the Immunogenicity of Melanoma-Associated Antigen A3 for Stimulating Antitumor Immune Responses.

  2016cites this paper
• Driving gene-engineered T cell immunotherapy of cancer

  2016cites this paper
• Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients

  2016cites this paper
• Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy

  2016cites this paper
• The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

  2016cites this paper
• An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells

  2016cites this paper
• Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4

  2016cites this paper
• MAGE-A3: an immunogenic target used in clinical practice.

  2015cites this paper
• Understanding the mechanism of cure in testicular cancer

  2014cites this paper
• Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients.

  2014cites this paper
• Ustekinumab Improves Psoriasis without Suppressing Tumor Antigen-Specific Cytotoxic T Lymphocytes

  2014cites this paper
• Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism.

  2014cites this paper
• Vaccinated with a MAGE-3 Protein Frequencies in Melanoma Patients Monitoring of Anti-Vaccine CD4 T Cell

  2013cites this paper
• Monitoring immune responses in dendritic cell based vaccination with a focus on in vivo imaging

  2013cites this paper
• Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients.

  2013cites this paper
• Lentiviral vectors: a versatile tool to fight cancer.

  2013cites this paper
• Establishment of a stable T lymphoma cell line transduced with HLA-A*24:02-restricted WT1-specific TCR genes and its application to antigen-specific immunomonitoring.

  2013cites this paper
• Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

  2013cites this paper
• T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients

  2013cites this paper
• Novel immunodominant epitopes derived from MAGE-A3 and its significance in serological diagnosis of gastric cancer

  2013cites this paper
• Clinical Studies Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Speci fi c T-Cell Responses in Melanoma Patients

  2013cites this paper
• Récepteurs de lymphocyte t reconnaissant mage-a3 restreint au cmh de classe ii

  2013cites this paper
• Ongoing adaptive immune responses in the microenvironment of melanoma metastases

  2013cites this paper
• Molecular engineering of high affinity T-cell receptors for bispecific therapeutics

  2013cites this paper
• Récepteurs des lymphocytes t reconnaissant un gène mage restreint par hla-a1 ou hla-cw7

  2012cites this paper
• 识别hla-a1-或hla-cw7-限制的mage的t细胞受体

  2012cites this paper
• Recognition of a Natural WT 1 Epitope by a Modified WT 1 Peptide-specific T-Cell Receptor

  2012cites this paper
• Improving the clinical efficacy of cancer vaccines by targeting immune suppression in human tumors

  2012cites this paper
• Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.

  2012cites this paper
• Melanoma Antigens Recognized by T Lymphocytes

  2012cites this paper
• Structure-activity relationship of T-cell receptors based on alanine scanning.

  2011cites this paper
• Isolierung und Charakterisierung tumorassoziierter MHC- Klasse-I- und Klasse-II-Peptide aus soliden Nierenzell- und Cholangiozellulären Karzinomen

  2011cites this paper
• WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval

  2011cites this paper
• Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.

  2011cites this paper
• Tumor vaccines and beyond.

  2011cites this paper
• A MAGE‐C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy

  2011cites this paper
• Oligomannose‐coated liposomes efficiently induce human T‐cell leukemia virus‐1‐specific cytotoxic T lymphocytes without adjuvant

  2011cites this paper
• Preclinical Qualification of a New Multi-antigen Candidate Vaccine for Metastatic Melanoma

  2010cites this paper
• Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

  2010cites this paper
• Récepteurs des lymphocytes t

  2010cites this paper
• Naturally occurring tumor‐specific CD8+ T‐cell precursors in individuals with and without cancer

  2010cites this paper
• WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE

  2010cites this paper
• Determinants of cancer immunotherapy success

  2010cites this paper
• Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.

  2009cites this paper
• Comparison of stable human Treg and Th clones by transcriptional profiling

  2009cites this paper
• In vitro performance of an injectable hydrogel/microsphere based immunocyte delivery system for localised anti-tumour activity.

  2009cites this paper
• HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor

  2009cites this paper
• Multiepitope peptide‐loaded virus‐like particles as a vaccine against hepatitis B virus–related hepatocellular carcinoma

  2009influential citation
• About human tumor antigens to be used in immunotherapy.

  2008cites this paper
• Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate

  2008cites this paper
• Delivery strategies of melanoma vaccines: an overview

  2008cites this paper
• Sperm Protein 17 is a Suitable Target for Adoptive T-cell–based Immunotherapy in Human Ovarian Cancer

  2008cites this paper
• Antigenic Peptide Vaccination: Provoking Immune Response and Clinical Benefit for Cancer

  2008cites this paper
• Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: Implications for immunotherapy

  2008cites this paper
• Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.

  2008cites this paper
• Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals.

  2008cites this paper
• Targets for active immunotherapy against pediatric solid tumors

  2008cites this paper
• Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma

  2008cites this paper
• Gentherapie

  2008cites this paper
• Plasmid DNA and viral vector-based vaccines for the treatment of cancer.

  2007cites this paper
• Specific CD8+ T cell responses to HLA-A2 restricted MAGE-A3 p271–279 peptide in hepatocellular carcinoma patients without vaccination

  2007cites this paper
• Current approaches in dendritic cell generation and future implications for cancer immunotherapy

  2007cites this paper
• Tumor immune escape mediated by indoleamine 2,3-dioxygenase.

  2007cites this paper
• The role of Wilms' tumor gene peptide-specific cytotoxic T lymphocytes in immunologic selection of a paroxysmal nocturnal hemoglobinuria clone.

  2007cites this paper
• Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform.

  2007cites this paper
• Tumor immunotherapy in melanoma: on the dawn of a new era?

  2007cites this paper
• Vaccination for treatment and prevention of cancer in animal models.

  2006cites this paper
• From pathogen to medicine: HIV‐1‐derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy

  2006cites this paper
• Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells

  2006cites this paper
• A new dendritic cell vaccine generated with interleukin-3 and interferon-β induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients

  2006cites this paper
• Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors

  2006cites this paper
• Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195–203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules

  2006cites this paper
• Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells

  2006cites this paper
• Human T cell responses against melanoma.

  2006cites this paper
• A Novel Approach to Characterize Clonality and Differentiation of Human Melanoma-Specific T Cell Responses: Spontaneous Priming and Efficient Boosting by Vaccination1

  2006cites this paper
• by Vaccination Spontaneous Priming and Efficient Boosting Melanoma-Specific T Cell Responses: and Differentiation of Human A Novel Approach to Characterize Clonality

  2006cites this paper
• Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1

  2006cites this paper
• Cancer vaccines: the challenge of developing an ideal tumor killing system.

  2005cites this paper
• Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia.

  2005cites this paper
• Spontaneous T-cell responses against peptides derived from the Taxol resistance–associated gene-3 (TRAG-3) protein in cancer patients

  2005cites this paper
• High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens

  2005cites this paper
• A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma

  2005cites this paper
• Monitoring of Anti-Vaccine CD4 T Cell Frequencies in Melanoma Patients Vaccinated with a MAGE-3 Protein1

  2005cites this paper
• Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes

  2005cites this paper
• Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.

  2005cites this paper